PDUFA Dates 2027: Complete FDA Drug Approval Calendar and Upcoming Decisions

PDUFA Dates 2027: Complete FDA Drug Approval Calendar and Upcoming Decisions

Key Takeaways

How PDUFA Dates Are Determined

The PDUFA Date Calculation Process

The path from application submission to PDUFA date assignment follows a defined sequence under 21 CFR 314.101 (NDAs) and 21 CFR 601.2 (BLAs):

Step 1: Application Submission (Day 0)

The sponsor submits a complete NDA or BLA to FDA via the Electronic Submissions Gateway (ESG) in eCTD format. The submission date is considered Day 0 but does not start the PDUFA review clock.

Step 2: User Fee Payment

Under Section 736(a) of the FD&C Act, the sponsor must pay the applicable Prescription Drug User Fee when the application is submitted. Because FDA updates the fee schedule annually, sponsors should confirm the current fee in the applicable Federal Register notice and on FDA's user fee page before filing.

Step 3: Filing Review (Days 1-60)

FDA conducts a 60-day filing review to determine whether the application is sufficiently complete for substantive review. Possible outcomes:

• Filed: Application accepted for review; PDUFA clock begins
• Refuse to File (RTF): Application rejected as incomplete under 21 CFR 314.101(d)
• Filed with issues: Application accepted but deficiencies noted for resolution during review

Step 4: PDUFA Date Assignment

Upon filing, FDA calculates the PDUFA date:

When PDUFA Dates Become Public

FDA does not publish a comprehensive calendar of pending PDUFA dates. The confidentiality provisions under 21 CFR 314.430 prohibit FDA from disclosing the existence of pending applications unless the sponsor has already made the information public.

PDUFA dates typically become known through:

For 2027 PDUFA dates, most will first become known during Q2-Q4 2026 as sponsors announce FDA acceptance of their applications.

Types of PDUFA Dates: NME vs BLA vs Efficacy Supplement

Not all PDUFA dates carry the same significance. Understanding the distinctions between application types is critical for interpreting the 2027 calendar.

New Molecular Entity (NME) PDUFA Dates

An NME PDUFA date represents FDA's review deadline for a drug containing an active moiety never previously approved under Section 505 of the FD&C Act. These are the most closely watched PDUFA dates because they represent entirely new treatments.

NME characteristics:

• First-ever approval of the active ingredient
• Typically receives the most intensive FDA review
• Reviewed by a full multidisciplinary team (clinical, pharmacology, chemistry, statistics)
• Subject to Advisory Committee review more frequently than supplements
• Post-marketing requirements (PMRs) commonly attached at approval

Under PDUFA VII, NME review timelines follow the same 10-month (standard) or 6-month (priority) goals, but NME reviews historically receive closer scrutiny. FDA's Center for Drug Evaluation and Research (CDER) publishes annual NME approval statistics in its CDER Annual Reports.

Biologics License Application (BLA) PDUFA Dates

BLA PDUFA dates apply to biological products reviewed by CDER or the Center for Biologics Evaluation and Research (CBER) under Section 351 of the Public Health Service Act. Since the Biologics Price Competition and Innovation Act (BPCIA) of 2010, original BLAs follow the same PDUFA timeline goals as NDAs.

BLA-specific considerations:

• Biological products include monoclonal antibodies, vaccines, cell therapies, gene therapies, and blood products
• Manufacturing inspections are particularly critical for biologics (facility-specific licenses)
• CBER-reviewed products (e.g., gene therapies, cell therapies) may have additional review complexity
• Under the Biosimilar User Fee Act (BSUFA), biosimilar BLAs have separate fee structures but similar timeline goals

Efficacy Supplement PDUFA Dates

Efficacy supplements (sNDAs and sBLAs) seek new indications, new patient populations, or new dosage regimens for already-approved drugs. These have their own PDUFA dates under PDUFA VII.

“

Key Distinction: Resubmissions (following a CRL) have shorter PDUFA timelines than original submissions because FDA has already reviewed much of the data. A Class 1 resubmission involves minor changes; Class 2 involves significant new data.

How to Read the Calendar

When reviewing the 2027 PDUFA calendar below, note these distinctions:

PDUFA VII Context: The Framework Governing 2027 Dates

PDUFA VII, reauthorized by Congress in September 2022 as part of the Food and Drug Omnibus Reform Act (FDORA), covers fiscal years 2023 through 2027. FY 2027 (October 1, 2026 - September 30, 2027) is the final year of the current authorization cycle.

PDUFA VII Performance Goals Applicable to 2027

PDUFA VII Enhancements Affecting 2027 Reviews

PDUFA VII introduced several commitments that will be fully operational for 2027 reviews:

1. Mid-Cycle Communications: FDA committed to providing a mid-cycle communication to sponsors for all standard review applications, typically around month 5-6, summarizing outstanding issues and review status.
2. Pre-Submission Interactions: Enhanced pre-submission meeting programs, including Type A, B, and C meetings with defined FDA response timelines (per FDA Guidance, "Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products," December 2023).
3. Real-World Evidence (RWE): PDUFA VII expanded FDA's capacity to evaluate real-world evidence in regulatory decision-making, building on the framework established by the 21st Century Cures Act (Section 3022).
4. Rare Disease Review: Enhanced review pathways for rare disease treatments, including expanded use of flexible trial designs and natural history data.

PDUFA VIII Reauthorization Impact

PDUFA VII runs through September 30, 2027. Sponsors tracking late-2027 reviews should monitor FDA and congressional reauthorization activity, but this article does not predict operational consequences beyond that statutory end date.

2027 PDUFA Dates: Quarterly Calendar

The following quarterly tables provide the framework for tracking 2027 FDA drug approval dates. Specific entries will be updated as sponsors publicly disclose their application timelines.

“

Note: FDA does not publish a public calendar of pending PDUFA dates. All dates below are compiled from sponsor disclosures in SEC filings, press releases, and earnings calls. Dates are subject to change due to Major Amendments, Complete Response Letters, or sponsor-initiated delays.

Q1 2027 (January - March)

Confirmed Q1 2027 dates should be added only after a sponsor publicly discloses the FDA action date. Until then, treat this quarter as an empty tracking window rather than a predictive calendar.

Q2 2027 (April - June)

Confirmed Q2 2027 dates should be listed only when supported by sponsor disclosures such as press releases, earnings materials, or SEC filings.

Q3 2027 (July - September)

Q3 2027 entries should remain blank until companies publicly confirm the associated FDA goal dates.

Q4 2027 (October - December)

Q4 2027 entries should be populated only from public sponsor disclosures or post-decision FDA records.

“

How to use this calendar: Treat it as a tracking framework, not a predictive list. Add entries only when the company or a formal filing makes the date public.

Historical Context: FDA Approval Trends Leading Into 2027

Understanding recent FDA approval patterns helps set expectations for the 2027 PDUFA calendar.

FDA Novel Drug Approvals by Year

Source: FDA CDER Annual Reports and Novel Drug Approvals publications

Key Trends Relevant to 2027

1. Oncology Dominance

Oncology consistently represents the largest therapeutic area for NME and BLA approvals, typically accounting for 25-35% of annual novel approvals. The 2027 calendar is expected to follow this pattern, with multiple oncology agents in late-stage development.

2. Cell and Gene Therapy Growth

Following FDA's approval of multiple cell and gene therapies since 2017 (starting with Kymriah and Yescarta), the 2027 pipeline includes several gene therapy candidates. These BLAs, reviewed by CBER's Office of Tissues and Advanced Therapies (OTAT), may carry unique review considerations.

3. Accelerated Approval Confirmatory Studies

Under the Accelerated Approval Integrity Act (part of FDORA, December 2022), sponsors with products granted accelerated approval must complete confirmatory studies. Several 2027 PDUFA dates may involve supplemental applications converting accelerated approvals to traditional approval based on confirmatory trial results.

4. Biosimilar Wave

The biosimilar pipeline continues to expand following the BPCIA pathway. Multiple biosimilar BLAs are expected to reach PDUFA dates in 2027, particularly for adalimumab, bevacizumab, and other high-revenue reference products.

FDA On-Time Performance

PDUFA performance is reported by FDA, but this article avoids restating annual percentages without linking directly to the relevant performance reports. For current performance data, check FDA's published PDUFA dashboards and annual performance materials.

What Happens on a PDUFA Date

On the PDUFA date, FDA takes one of three actions:

1. Approval

FDA issues an Approval Letter, granting authorization to market the drug in the United States. The approval letter specifies approved indications, labeling, and any post-marketing requirements (PMRs) or commitments (PMCs) under 21 CFR 314.510 or 601.14.

2. Complete Response Letter (CRL)

FDA issues a CRL under 21 CFR 314.110, identifying deficiencies that preclude approval. A CRL does not reject the application permanently but requires the sponsor to address identified issues and resubmit. Common CRL reasons include:

3. Major Amendment Extension

If FDA determines it needs additional time due to significant new information (a Major Amendment per PDUFA VII commitment letter), the PDUFA date may be extended by 3 months. This extension is calculated from the date FDA receives the sponsor's response to the information request, not from the date FDA issues the request.

Early Actions

FDA is not required to wait until the PDUFA date to act. Some applications are approved before the target date, but the exact frequency varies by year and application mix.

How to Track PDUFA Dates 2027 Independently

Primary Sources

Setting Up Alerts

For comprehensive 2027 PDUFA date tracking:

1. Google Alerts: Create alerts for "[Drug name] PDUFA" and "[Company name] FDA approval" for each pipeline drug of interest
2. SEC Filing Alerts: Monitor EDGAR for 8-K filings from companies with late-stage pipelines
3. FDA Listserv: Subscribe to FDA's Drug Information email lists at fda.gov for real-time approval announcements
4. ClinicalTrials.gov RSS: Set up RSS feeds for trials in Phase 3 completion

Interpreting Timeline Signals

When a sponsor announces a PDUFA date, you can reverse-calculate key milestones:

Factors That Could Shift 2027 PDUFA Dates

Several factors may cause individual PDUFA dates to move:

Sponsor-Side Factors

• Rolling submissions: Under Fast Track designation (Section 506(b) of the FD&C Act), sponsors may submit completed sections of an NDA/BLA as they are ready. The PDUFA date is calculated from the filing date of the last section received.
• Major Amendment responses: If FDA issues a Major Amendment request, the sponsor's response time directly affects the new PDUFA date.
• Withdrawal: Sponsors may voluntarily withdraw an application before the PDUFA date, typically if FDA signals a likely CRL.

FDA-Side Factors

• Operational disruptions: Sponsor delays, major amendments, inspection constraints, or other operational issues can move a target action date.
• Advisory Committee scheduling: If FDA convenes an Advisory Committee meeting, the review timeline may need to accommodate committee scheduling.
• Inspection delays: GMP or GCP inspection delays (e.g., international site access issues) can push PDUFA dates.

References